MECP2 and glioblastoma: In parallel, CRISPRi/dCas9-KRAB-MeCP2 and gRNAs targeting CD97 (dCAS9KRAB-MeCP2-CD97sgRNA) were transduced into U251 GBM cells, to create U251 control (U251-dCas9-KRAB-MeCP2) and U251 CD97 knockdown (U251-dCAS9-KRAB-MeCP2-CD97sgRNA) cells.